Bangkok--Mar 23--UNAIDS
Geneva, 22 March 2001 - WHO and UNAIDS welcome the commitment of pharmaceutical companies to improving people’s access to care for HIV infection. One of these companies, Cipla, has announced its offer to work with MSF to bring HIV-related medicines at affordable prices to the people who need them in developing countries.
A meeting took place today at WHO between staff from Cipla, WHO, UNAIDS, the European Commission and MSF, in order for the UN organizations to get clarification on a range of issues relating to Cipla’s recent offer to make reduced price triple combination therapy available in developing countries.
Issues raised included pre-qualification, registration requirements, supply logistics, technology transfer and validity of patents.
WHO and UNAIDS noted that an overall framework to combating the HIV/AIDS epidemic and other serious infectious diseases in poor countries is a priority. This framework must encompass prevention, care, treatment and healthcare systems development. Moreover, ensuring that antiretroviral and other AIDS drugs reach those who need them and are used effectively means that questions of financing and clinical feasibility will also have to be addressed.
The information supplied by Cipla today will be evaluated to see how Cipla’s offer can be included in the information that the UN makes available to interested governments and nongovernmental organizations through its Accelerating Access Initiative.
The approach of the UNAIDS Cosponsors and the Secretariat is to help countries identify all legitimate suppliers of affordable medicines of assured quality, including those in both the generics industry and the research and development-based industry.
The UN has identified, through a public call for Expressions of Interest to manufacturers of HIV-related pharmaceuticals and diagnostic equipment, 34 suppliers of HIV-related medicines and diagnostics, 29 of which are from the generics industry. An analysis of these offers will be made publicly available in mid-2001. Cipla’s offer will be included in this analysis.
For more information, please contact Pensri Tasnavites, UNAIDS Media
Advisor, Bangkok, Tel. (+ 66 2) 257 0300, Fax. (+ 66 2) 257 0312, Anne
Winter, UNAIDS, Geneva, (+41 22) 791 4577 Dominique de Santis, UNAIDS,
Geneva, (+41 22) 791 4509 or Andrew Shih, UNAIDS, New York, (+ 1 212) 584
5024. You may also visit the UNAIDS Home Page on the Internet for more
information about the programme (http://www.unaids.org). End.
-AN-